Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.

doi:10.1002/cam4.3655

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.

Cancer medicine - 1 Feb 2021

Wu Chengde, Rao Xiang, Lin Wei

Abstract excerpt

PURPOSE: TP53 mutation, one of the most frequent mutations in early-stage lung adenocarcinoma (LUAD), triggers a series of alterations in the immune landscape, progression, and clinical outcome of early-stage LUAD. Our study was designed to unravel the effects of TP53 mutation on the immunophenotype of early-stage LUAD and formulate a TP53-associated immune prognostic model (IPM) that can estimate prognosis in...

Topics

Adenocarcinoma of Lung
Biomarkers, Tumor
Databases, Genetic
Female
Follow-Up Studies
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
Male
Middle Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Nomograms

Prognosis

ROC Curve

Retrospective Studies

Survival Rate

Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 33314730
DOI: 10.1002/cam4.3655
PMCID: PMC7897963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.PMID 33314730Read ↗

Clinical and Prognostic Implications of an Immune-Related Risk Model Based on TP53 Status in Lung AdenocarcinomaSemantic proximity Read ↗

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.Semantic proximity Read ↗

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.Semantic proximity Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinomaSemantic proximity Read ↗

An Immune Gene Signature for Prediction of Overall Survival and Response to Immune Checkpoint Inhibitors Therapy in Patients with Lung AdenocarcinomaSemantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genesSemantic proximity Read ↗

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Semantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.